GLP 1 Analogues Market Size 2025-2029
The glp 1 analogues market size is forecast to increase by USD 100.1 billion, at a CAGR of 25.3% between 2024 and 2029.
The global GLP 1 analogues market is expanding, driven by the increasing global prevalence of Type 2 Diabetes and obesity. These conditions have created a substantial patient population in need of advanced pharmacological interventions. The development of multi-agonist therapies, a key market trend, is redefining treatment standards by offering superior efficacy in glycemic control and weight loss. These advanced therapies, which include dual and triple agonists, engage multiple hormonal pathways to deliver more comprehensive physiological responses. Innovations in this area, including those for oncology drugs, are setting new benchmarks for managing complex metabolic disorders. This progress highlights a continuous pursuit of more effective therapeutic solutions, aligning with advancements in areas like single cell analysis and hematology analyzers.High therapy costs and reimbursement challenges limit broader market penetration. The premium pricing of these advanced biological medications creates financial burdens for healthcare systems and patients, leading to access restrictions through prior authorizations or strict eligibility criteria. For those without adequate insurance coverage, out-of-pocket expenses can be prohibitive, affecting treatment adherence. This financial barrier is particularly significant in developing economies, where it restricts widespread adoption despite the growing need for effective treatments. Addressing these cost and reimbursement hurdles is essential for ensuring that the benefits of these therapies, comparable in impact to advancements in particle size analyzer or breath analyzers technology, can reach a wider global population requiring intervention.
What will be the Size of the GLP 1 Analogues Market during the forecast period?
Explore in-depth regional segment analysis with market size data - historical 2019 - 2023 and forecasts 2025-2029 - in the full report.
Request Free Sample
The market's landscape is continually being redefined by advancements in therapeutic applications and drug delivery systems. Ongoing research into multi-agonist therapies, which target multiple receptors like GLP-1 and GIP, is setting new efficacy standards for glycemic control improvement and chronic weight management. These developments are supported by deep analysis of metabolic pathways, similar to the precision required in hematology analyzers. The shift toward oral peptide delivery technologies addresses patient adherence challenges, expanding the potential user base beyond those comfortable with subcutaneous injection formulations. This constant innovation is reshaping clinical guidelines and treatment algorithms globally.Exploration into new therapeutic indications is broadening the market's scope beyond its original focus. Landmark cardiovascular outcome trials have established the cardiorenal protective effects of these agents, integrating them into cardiology and nephrology practices. Research is actively investigating their potential in treating conditions such as non-alcoholic steatohepatitis and certain neurodegenerative disorders. This expansion is transforming the market into a comprehensive metabolic health platform. The sophisticated research involved often mirrors advancements in other medical fields, such as the use of a particle size analyzer or single cell analysis to understand drug interactions at a micro-level.
How is this GLP 1 Analogues Industry segmented?
The glp 1 analogues industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029, as well as historical data from 2019 - 2023 for the following segments.
- Application
- Route of administration
- Subcutaneous injection
- Oral administration
- Distribution channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Geography
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- The Netherlands
- Asia
- Rest of World (ROW)
By Application Insights
The type 2 diabetes mellitus segment is estimated to witness significant growth during the forecast period.
The application of GLP-1 analogues in Type 2 Diabetes Mellitus (T2DM) remains the foundational segment, driven by their established efficacy in improving glycemic control. These agents address multiple pathophysiological defects by stimulating glucose-dependent insulin secretion and suppressing glucagon release. Their benefits extend beyond HbA1c reduction to include weight loss and a reduced risk of hypoglycemia. Long-acting formulations have significantly enhanced patient adherence, making them a preferred therapeutic option in diabetes management drugs and other metabolic disorder treatments.
This core segment, which accounts for over 60% of the market, is sustained by the growing recognition of the cardiorenal protective effects offered by certain GLP-1 analogues. Updated clinical guidelines increasingly position them as first-line or early add-on therapy, especially for patients with cardiovascular or chronic kidney disease. This shift toward holistic patient outcomes, combined with the rising global prevalence of T2DM, ensures continued demand for these agents as a cornerstone therapy in managing this complex chronic condition.
Request Free Sample
The Type 2 diabetes mellitus segment was valued at USD 14.7 billion in 2019 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 52.8% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Request Free Sample
The North America market for GLP-1 analogues is the largest globally, shaped by a high prevalence of type 2 diabetes and obesity, alongside an advanced healthcare infrastructure. The region benefits from high per capita healthcare expenditure and generally favorable reimbursement policies, which facilitate the aggressive adoption of innovative therapies. Strong physician awareness and comprehensive clinical guidelines that endorse these agents as preferred treatments further solidify market penetration. The area's robust pharmaceutical research landscape fosters continuous innovation and rapid introduction of new formulations.
A key factor in this region's dominance is its significant contribution to market expansion. The North America region is projected to contribute over 52% of the market's incremental growth, underscoring its pivotal role in the global landscape. This is supported by strong public and private insurance coverage, which provides access to these expensive treatments for a large patient population. The emphasis on preventative care and long-term management of chronic metabolic diseases ensures sustained demand, reinforcing North America's leading position in the global market.
Market Dynamics
Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The global GLP-1 analogues market is rapidly expanding, fueled by the proven efficacy of GLP-1 analogues for obesity management and the introduction of long-acting GLP-1 formulations for diabetes. A key industry focus is on oral GLP-1 receptor agonist development to improve patient adherence to injectable GLP-1 therapies. The significant cardiovascular benefits of incretin mimetics, demonstrated by the positive impact of GLP-1 analogues on MACE, have been pivotal. Clinicians are increasingly focused on managing side effects of GLP-1 therapy to optimize patient outcomes. As the role of GLP-1 analogues in primary care grows, the cost-effectiveness of GLP-1 analogues becomes a central topic for market access. These agents are also being explored for GLP-1 analogues in chronic kidney disease, broadening their clinical utility and highlighting their systemic benefits.The future of this market is defined by advanced therapeutic strategies and pipeline innovation. The future pipeline of multi-agonist incretins is highly anticipated, with dual GIP/GLP-1 receptor agonist therapies showing immense promise. Ongoing studies on the comparative efficacy of GLP-1 agonists and the benefits of combination therapy with SGLT2 inhibitors continue to shape treatment paradigms. Exploratory research into GLP-1 based treatments for NASH and potential GLP-1 analogues and neuroprotective effects represents new frontiers. Successfully navigating the regulatory pathways for GLP-1 analogues and overcoming manufacturing challenges of peptide-based drugs are critical for market entrants. Furthermore, the development of GLP-1 analogues for pediatric obesity and the collection of real-world data on GLP-1 outcomes are essential for defining the long-term value proposition of this drug class.
What are the key market drivers leading to the rise in the adoption of GLP 1 Analogues Industry?
- The escalating global prevalence of type 2 diabetes and obesity is the foremost driver shaping the market landscape.
The escalating global incidence of Type 2 Diabetes Mellitus (T2DM) and obesity is the primary factor driving expansion in the global GLP-1 analogues market. These intertwined epidemics create a vast patient pool requiring advanced pharmacological interventions that offer glucose-dependent insulin secretion and glucagon release suppression. GLP-1 analogues provide highly effective therapeutic solutions, improving glycemic control, promoting weight loss, and offering cardiorenal protective effects. As obesity rates climb, the incidence of diabetes also rises, increasing the demand for efficacious drugs. A deeper understanding of these chronic metabolic disorders has led to earlier diagnosis and more aggressive treatment strategies, further stimulating demand for therapies with comprehensive benefits like improved beta-cell function and satiety signaling pathways.Growing awareness and improved diagnostic capabilities for metabolic disorders serve as a significant catalyst for market growth. Enhanced public health initiatives and routine screening programs facilitate earlier detection of T2DM and obesity, expanding the number of individuals eligible for treatment. This increased diagnostic vigilance, combined with a greater understanding of the long-term complications, fosters a willingness among patients to seek and adhere to therapeutic regimens. With over 52% of the market's incremental growth concentrated in a single region, access to diagnostic tools and digital health platforms supports this trend by promoting self-monitoring and early risk identification, which directly translates into increased prescription rates for advanced pharmacological agents.
What are the market trends shaping the GLP 1 Analogues Industry?
- A key market trend is the ongoing development of advanced multi-agonist therapies that target multiple hormonal pathways.
The development of multi-agonist therapies is a transformative trend, moving beyond single-receptor agents to compounds that activate multiple incretin receptors like GLP-1 and GIP. This approach leverages synergistic effects to achieve superior efficacy, including more pronounced reductions in HbA1c and greater weight loss. These advanced therapies, including dual agonist compounds and triple agonist compounds, set new benchmarks by addressing multiple pathophysiological defects simultaneously. This innovation highlights the industry's commitment to creating more potent options for patients with complex metabolic disorders, impacting everything from patient tolerability profiles to clinical trial endpoints, much like the precision seen in pathology instruments. The success of these therapies paves the way for increasingly sophisticated pharmacological agents.The expansion of indications beyond Type 2 Diabetes is fundamentally reshaping the market, turning a diabetes-centric focus into a broader metabolic health platform with applications similar to those in the oncology drugs space. The approval of GLP-1 analogues for chronic weight management has unlocked a massive new patient population. Furthermore, robust evidence for cardiovascular risk reduction has integrated these therapies into cardiology practice, with ongoing research exploring potential in other conditions like NASH and chronic kidney disease. This versatility positions these compounds as highly valuable therapeutic agents across a spectrum of diseases, reinforcing their long-term growth trajectory. A secondary region contributes to approximately 23% of the geographic opportunity, indicating broadening global adoption.
What challenges does the GLP 1 Analogues Industry face during its growth?
- The high cost of therapy coupled with complex reimbursement challenges presents a significant barrier to market expansion.
The high cost of GLP-1 analogue therapies presents a significant challenge to market penetration and patient access. These advanced peptide-based drug manufacturing medications carry premium price tags, creating a substantial financial burden on healthcare systems and patients. Reimbursement policies and formulary coverage decisions are therefore critical determinants of access, with many payers requiring prior authorizations or imposing strict eligibility criteria that limit treatment initiation. For uninsured patients, out-of-pocket expenses can be prohibitive. This challenge necessitates strategic pricing models and patient assistance programs to highlight the long-term health and economic benefits, including reduced downstream complications. Emerging geographies, while promising, represent just over 15% of the market opportunity, where high costs are an even greater barrier.Side effects and patient tolerability issues are a notable challenge to the widespread adoption of GLP-1 analogues. Gastrointestinal adverse events, such as nausea, vomiting, and diarrhea, are common, particularly during dose escalation protocols, and can lead to treatment discontinuation. Although often transient, these side effects impact patient adherence. Less common but more serious concerns, such as pancreatitis risk monitoring and potential thyroid c-cell tumors, require careful patient screening. Additionally, fears associated with injectable pen devices contribute to patient reluctance. For oral formulations, specific administration instructions can pose adherence challenges. These tolerability issues underscore the need for innovation aimed at developing drugs with improved side effect profiles and more convenient drug delivery systems.
Exclusive Customer Landscape
The glp 1 analogues market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the glp 1 analogues market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, glp 1 analogues market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
Amgen Inc. - Key offerings in the market encompass a range of pharmaceutical agents that mimic the action of glucagon-like peptide 1. These products are designed for improved glycemic control and weight management, with applications extending to cardiovascular risk reduction. The portfolio includes various formulations, such as subcutaneous injections administered via user-friendly pen devices and innovative oral peptide delivery systems, catering to diverse patient needs and preferences. Advanced offerings feature multi-agonist therapies, including dual and triple agonist compounds, which target multiple receptors to enhance therapeutic efficacy. These therapies address critical unmet needs in metabolic health, providing comprehensive solutions for chronic conditions like type 2 diabetes, obesity, and related comorbidities such as non-alcoholic steatohepatitis and chronic kidney disease.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- Amgen Inc.
- Amneal Pharmaceuticals Inc.
- Ascendis Pharma AS
- AstraZeneca Plc
- Boehringer Ingelheim Intl. GmbH
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- Innovent Biologics Inc.
- Johnson and Johnson Services Inc.
- LG Chem Ltd.
- Merck and Co. Inc.
- Novo Nordisk AS
- Pfizer Inc.
- Sanofi SA
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Glp 1 Analogues Market
In April 2024, Novo Nordisk initiated a large-scale Phase 3 clinical trial to investigate the efficacy of its GLP-1 analogue, semaglutide, in reducing cardiovascular events in patients with established cardiovascular disease but without diabetes.In March 2024, Eli Lilly announced that its GLP-1/GIP receptor agonist, tirzepatide (MARKETED AS ZEPBOUND), received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for weight management in adults with obesity.In March 2024, Boehringer Ingelheim and Zealand Pharma announced positive topline results from a Phase 2 trial of their dual GLP-1/glucagon receptor agonist, survodutide, showing significant improvement in liver fibrosis for patients with metabolic dysfunction-associated steatohepatitis (MASH).In January 2024, Amgen reported positive topline data from its Phase 2 study of MariTide (AMG 133), an investigational dual GIPR antagonist and GLP-1R agonist, which demonstrated significant dose-dependent weight loss in patients with obesity, with or without diabetes.
Research Analyst Overview
The market for glucagon-like peptide-1 analogues is shaped by the fundamental mechanism of incretin hormone action, where GLP-1 receptor activation drives therapeutic benefits. This activation stimulates glucose-dependent insulin secretion, leads to glucagon release suppression, and causes gastric emptying delay for glycemic control improvement. A key aspect involves influencing appetite regulation mechanisms, which is crucial for applications in chronic weight management. The focus extends to cardiovascular risk reduction, with an emphasis on preventing major adverse cardiovascular events and providing cardiorenal protective effects. This therapeutic expansion fuels the creation of multi-agonist therapies, including dual agonist compounds and triple agonist compounds targeting GIP receptor agonists, often studied alongside SGLT2 inhibitors.Innovation is moving beyond subcutaneous injection formulations administered via injectable pen devices, as the pursuit of viable oral peptide delivery intensifies to create a more comprehensive metabolic health platform. This platform sees therapeutic indications expansion into fields like non-alcoholic steatohepatitis and chronic kidney disease, with such explorations constituting a 22% portion of new pre-clinical testing. The development pathway, including the bioanalytical testing phase, incorporates strict dose escalation protocols while monitoring patient tolerability profiles and safety signals like pancreatitis risk monitoring and concerns over thyroid c-cell tumors. Next-generation biotherapeutics are being shaped by advanced peptide-based drug manufacturing, nanotechnology in drugs, and even early-stage research into 3d bioprinting pharmaceuticals, complemented by prescription digital therapeutics.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled GLP 1 Analogues Market insights. See full methodology.
|
Market Scope
|
|
Report Coverage
|
Details
|
|
Page number
|
288
|
|
Base year
|
2024
|
|
Historic period
|
2019 - 2023 |
|
Forecast period
|
2025-2029
|
|
Growth momentum & CAGR
|
Accelerating at a CAGR of 25.3%
|
|
Market growth 2024-2029
|
USD 100.1 billion
|
|
Market structure
|
Fragmented
|
|
YoY growth 2024-2029(%)
|
24.1%
|
|
Key countries
|
US, Canada, Mexico, Germany, UK, France, Italy, Spain, Russia, The Netherlands, China, India, Japan, South Korea, Indonesia, Thailand, Singapore, Brazil, Australia, UAE, South Africa, Saudi Arabia, Turkey
|
|
Competitive landscape
|
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
|
Request Free Sample
What are the Key Data Covered in this GLP 1 Analogues Market Research and Growth Report?
- CAGR of the GLP 1 Analogues industry during the forecast period
- Detailed information on factors that will drive the growth and forecasting between 2024 and 2029
- Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
- Accurate predictions about upcoming growth and trends and changes in consumer behaviour
- Growth of the market across North America, Europe, Asia, Rest of World (ROW)
- Thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the glp 1 analogues market growth of industry companies
We can help! Our analysts can customize this glp 1 analogues market research report to meet your requirements.
Get in touch
1 Executive Summary
- 1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Market Segmentation by Distribution Channel
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- Chart on Overview on criticality of inputs and factors of differentiation
- 2.3 Factors of disruption
- Chart on Overview on factors of disruption
- 2.4 Impact of drivers and challenges
- Chart on Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
- 3 Market Landscape
- 3.1 Market ecosystem
- Chart on Parent Market
- Data Table on - Parent Market
- 3.2 Market characteristics
- Chart on Market characteristics analysis
- 3.3 Value chain analysis
- Chart on Value chain analysis
4 Market Sizing
- 4 Market Sizing
- 4.1 Market definition
- Data Table on Offerings of companies included in the market definition
- 4.2 Market segment analysis
- 4.3 Market size 2024
- 4.4 Market outlook: Forecast for 2024-2029
- Chart on Global - Market size and forecast 2024-2029 ($ billion)
- Data Table on Global - Market size and forecast 2024-2029 ($ billion)
- Chart on Global Market: Year-over-year growth 2024-2029 (%)
- Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
- 5 Historic Market Size
- 5.1 Global GLP 1 Analogues Market 2019 - 2023
- Historic Market Size - Data Table on Global GLP 1 Analogues Market 2019 - 2023 ($ billion)
- 5.2 Application segment analysis 2019 - 2023
- Historic Market Size - Application Segment 2019 - 2023 ($ billion)
- 5.3 Route of Administration segment analysis 2019 - 2023
- Historic Market Size - Route of Administration Segment 2019 - 2023 ($ billion)
- 5.4 Distribution Channel segment analysis 2019 - 2023
- Historic Market Size - Distribution Channel Segment 2019 - 2023 ($ billion)
- 5.5 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ billion)
- 5.6 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ billion)
6 Qualitative Analysis
- 6 Qualitative Analysis
- 6.1 Impact of AI on global GLP 1 analogues market
7 Five Forces Analysis
- 7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 7.7 Market condition
- Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Application
- 8 Market Segmentation by Application
- 8.1 Market segments
- Chart on Application - Market share 2024-2029 (%)
- Data Table on Application - Market share 2024-2029 (%)
- 8.2 Comparison by Application
- Chart on Comparison by Application
- Data Table on Comparison by Application
- 8.3 Type 2 diabetes mellitus - Market size and forecast 2024-2029
- Chart on Type 2 diabetes mellitus - Market size and forecast 2024-2029 ($ billion)
- Data Table on Type 2 diabetes mellitus - Market size and forecast 2024-2029 ($ billion)
- Chart on Type 2 diabetes mellitus - Year-over-year growth 2024-2029 (%)
- Data Table on Type 2 diabetes mellitus - Year-over-year growth 2024-2029 (%)
- 8.4 Obesity management - Market size and forecast 2024-2029
- Chart on Obesity management - Market size and forecast 2024-2029 ($ billion)
- Data Table on Obesity management - Market size and forecast 2024-2029 ($ billion)
- Chart on Obesity management - Year-over-year growth 2024-2029 (%)
- Data Table on Obesity management - Year-over-year growth 2024-2029 (%)
- 8.5 Cardiovascular diseases - Market size and forecast 2024-2029
- Chart on Cardiovascular diseases - Market size and forecast 2024-2029 ($ billion)
- Data Table on Cardiovascular diseases - Market size and forecast 2024-2029 ($ billion)
- Chart on Cardiovascular diseases - Year-over-year growth 2024-2029 (%)
- Data Table on Cardiovascular diseases - Year-over-year growth 2024-2029 (%)
- 8.6 Market opportunity by Application
- Market opportunity by Application ($ billion)
- Data Table on Market opportunity by Application ($ billion)
9 Market Segmentation by Route of Administration
- 9 Market Segmentation by Route of Administration
- 9.1 Market segments
- Chart on Route of Administration - Market share 2024-2029 (%)
- Data Table on Route of Administration - Market share 2024-2029 (%)
- 9.2 Comparison by Route of Administration
- Chart on Comparison by Route of Administration
- Data Table on Comparison by Route of Administration
- 9.3 Subcutaneous injection - Market size and forecast 2024-2029
- Chart on Subcutaneous injection - Market size and forecast 2024-2029 ($ billion)
- Data Table on Subcutaneous injection - Market size and forecast 2024-2029 ($ billion)
- Chart on Subcutaneous injection - Year-over-year growth 2024-2029 (%)
- Data Table on Subcutaneous injection - Year-over-year growth 2024-2029 (%)
- 9.4 Oral administration - Market size and forecast 2024-2029
- Chart on Oral administration - Market size and forecast 2024-2029 ($ billion)
- Data Table on Oral administration - Market size and forecast 2024-2029 ($ billion)
- Chart on Oral administration - Year-over-year growth 2024-2029 (%)
- Data Table on Oral administration - Year-over-year growth 2024-2029 (%)
- 9.5 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ billion)
- Data Table on Market opportunity by Route of Administration ($ billion)
10 Market Segmentation by Distribution Channel
- 10 Market Segmentation by Distribution Channel
- 10.1 Market segments
- Chart on Distribution Channel - Market share 2024-2029 (%)
- Data Table on Distribution Channel - Market share 2024-2029 (%)
- 10.2 Comparison by Distribution Channel
- Chart on Comparison by Distribution Channel
- Data Table on Comparison by Distribution Channel
- 10.3 Hospital pharmacies - Market size and forecast 2024-2029
- Chart on Hospital pharmacies - Market size and forecast 2024-2029 ($ billion)
- Data Table on Hospital pharmacies - Market size and forecast 2024-2029 ($ billion)
- Chart on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
- Data Table on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
- 10.4 Retail pharmacies - Market size and forecast 2024-2029
- Chart on Retail pharmacies - Market size and forecast 2024-2029 ($ billion)
- Data Table on Retail pharmacies - Market size and forecast 2024-2029 ($ billion)
- Chart on Retail pharmacies - Year-over-year growth 2024-2029 (%)
- Data Table on Retail pharmacies - Year-over-year growth 2024-2029 (%)
- 10.5 Online pharmacies - Market size and forecast 2024-2029
- Chart on Online pharmacies - Market size and forecast 2024-2029 ($ billion)
- Data Table on Online pharmacies - Market size and forecast 2024-2029 ($ billion)
- Chart on Online pharmacies - Year-over-year growth 2024-2029 (%)
- Data Table on Online pharmacies - Year-over-year growth 2024-2029 (%)
- 10.6 Market opportunity by Distribution Channel
- Market opportunity by Distribution Channel ($ billion)
- Data Table on Market opportunity by Distribution Channel ($ billion)
11 Customer Landscape
- 11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12 Geographic Landscape
- 12.1 Geographic segmentation
- Chart on Market share by geography 2024-2029 (%)
- Data Table on Market share by geography 2024-2029 (%)
- 12.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
- 12.3 North America - Market size and forecast 2024-2029
- Chart on North America - Market size and forecast 2024-2029 ($ billion)
- Data Table on North America - Market size and forecast 2024-2029 ($ billion)
- Chart on North America - Year-over-year growth 2024-2029 (%)
- Data Table on North America - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - North America
- Data Table on Regional Comparison - North America
- 12.3.1 US - Market size and forecast 2024-2029
- Chart on US - Market size and forecast 2024-2029 ($ billion)
- Data Table on US - Market size and forecast 2024-2029 ($ billion)
- Chart on US - Year-over-year growth 2024-2029 (%)
- Data Table on US - Year-over-year growth 2024-2029 (%)
- 12.3.2 Canada - Market size and forecast 2024-2029
- Chart on Canada - Market size and forecast 2024-2029 ($ billion)
- Data Table on Canada - Market size and forecast 2024-2029 ($ billion)
- Chart on Canada - Year-over-year growth 2024-2029 (%)
- Data Table on Canada - Year-over-year growth 2024-2029 (%)
- 12.3.3 Mexico - Market size and forecast 2024-2029
- Chart on Mexico - Market size and forecast 2024-2029 ($ billion)
- Data Table on Mexico - Market size and forecast 2024-2029 ($ billion)
- Chart on Mexico - Year-over-year growth 2024-2029 (%)
- Data Table on Mexico - Year-over-year growth 2024-2029 (%)
- 12.4 Europe - Market size and forecast 2024-2029
- Chart on Europe - Market size and forecast 2024-2029 ($ billion)
- Data Table on Europe - Market size and forecast 2024-2029 ($ billion)
- Chart on Europe - Year-over-year growth 2024-2029 (%)
- Data Table on Europe - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Europe
- Data Table on Regional Comparison - Europe
- 12.4.1 Germany - Market size and forecast 2024-2029
- Chart on Germany - Market size and forecast 2024-2029 ($ billion)
- Data Table on Germany - Market size and forecast 2024-2029 ($ billion)
- Chart on Germany - Year-over-year growth 2024-2029 (%)
- Data Table on Germany - Year-over-year growth 2024-2029 (%)
- 12.4.2 UK - Market size and forecast 2024-2029
- Chart on UK - Market size and forecast 2024-2029 ($ billion)
- Data Table on UK - Market size and forecast 2024-2029 ($ billion)
- Chart on UK - Year-over-year growth 2024-2029 (%)
- Data Table on UK - Year-over-year growth 2024-2029 (%)
- 12.4.3 France - Market size and forecast 2024-2029
- Chart on France - Market size and forecast 2024-2029 ($ billion)
- Data Table on France - Market size and forecast 2024-2029 ($ billion)
- Chart on France - Year-over-year growth 2024-2029 (%)
- Data Table on France - Year-over-year growth 2024-2029 (%)
- 12.4.4 Italy - Market size and forecast 2024-2029
- Chart on Italy - Market size and forecast 2024-2029 ($ billion)
- Data Table on Italy - Market size and forecast 2024-2029 ($ billion)
- Chart on Italy - Year-over-year growth 2024-2029 (%)
- Data Table on Italy - Year-over-year growth 2024-2029 (%)
- 12.4.5 Spain - Market size and forecast 2024-2029
- Chart on Spain - Market size and forecast 2024-2029 ($ billion)
- Data Table on Spain - Market size and forecast 2024-2029 ($ billion)
- Chart on Spain - Year-over-year growth 2024-2029 (%)
- Data Table on Spain - Year-over-year growth 2024-2029 (%)
- 12.4.6 Russia - Market size and forecast 2024-2029
- Chart on Russia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Russia - Market size and forecast 2024-2029 ($ billion)
- Chart on Russia - Year-over-year growth 2024-2029 (%)
- Data Table on Russia - Year-over-year growth 2024-2029 (%)
- 12.4.7 The Netherlands - Market size and forecast 2024-2029
- Chart on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Data Table on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Chart on The Netherlands - Year-over-year growth 2024-2029 (%)
- Data Table on The Netherlands - Year-over-year growth 2024-2029 (%)
- 12.5 Asia - Market size and forecast 2024-2029
- Chart on Asia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Asia - Market size and forecast 2024-2029 ($ billion)
- Chart on Asia - Year-over-year growth 2024-2029 (%)
- Data Table on Asia - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Asia
- Data Table on Regional Comparison - Asia
- 12.5.1 China - Market size and forecast 2024-2029
- Chart on China - Market size and forecast 2024-2029 ($ billion)
- Data Table on China - Market size and forecast 2024-2029 ($ billion)
- Chart on China - Year-over-year growth 2024-2029 (%)
- Data Table on China - Year-over-year growth 2024-2029 (%)
- 12.5.2 India - Market size and forecast 2024-2029
- Chart on India - Market size and forecast 2024-2029 ($ billion)
- Data Table on India - Market size and forecast 2024-2029 ($ billion)
- Chart on India - Year-over-year growth 2024-2029 (%)
- Data Table on India - Year-over-year growth 2024-2029 (%)
- 12.5.3 Japan - Market size and forecast 2024-2029
- Chart on Japan - Market size and forecast 2024-2029 ($ billion)
- Data Table on Japan - Market size and forecast 2024-2029 ($ billion)
- Chart on Japan - Year-over-year growth 2024-2029 (%)
- Data Table on Japan - Year-over-year growth 2024-2029 (%)
- 12.5.4 South Korea - Market size and forecast 2024-2029
- Chart on South Korea - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Korea - Market size and forecast 2024-2029 ($ billion)
- Chart on South Korea - Year-over-year growth 2024-2029 (%)
- Data Table on South Korea - Year-over-year growth 2024-2029 (%)
- 12.5.5 Indonesia - Market size and forecast 2024-2029
- Chart on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Chart on Indonesia - Year-over-year growth 2024-2029 (%)
- Data Table on Indonesia - Year-over-year growth 2024-2029 (%)
- 12.5.6 Thailand - Market size and forecast 2024-2029
- Chart on Thailand - Market size and forecast 2024-2029 ($ billion)
- Data Table on Thailand - Market size and forecast 2024-2029 ($ billion)
- Chart on Thailand - Year-over-year growth 2024-2029 (%)
- Data Table on Thailand - Year-over-year growth 2024-2029 (%)
- 12.5.7 Singapore - Market size and forecast 2024-2029
- Chart on Singapore - Market size and forecast 2024-2029 ($ billion)
- Data Table on Singapore - Market size and forecast 2024-2029 ($ billion)
- Chart on Singapore - Year-over-year growth 2024-2029 (%)
- Data Table on Singapore - Year-over-year growth 2024-2029 (%)
- 12.6 Rest of World (ROW) - Market size and forecast 2024-2029
- Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
- Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
- Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Rest of World (ROW)
- Data Table on Regional Comparison - Rest of World (ROW)
- 12.6.1 Brazil - Market size and forecast 2024-2029
- Chart on Brazil - Market size and forecast 2024-2029 ($ billion)
- Data Table on Brazil - Market size and forecast 2024-2029 ($ billion)
- Chart on Brazil - Year-over-year growth 2024-2029 (%)
- Data Table on Brazil - Year-over-year growth 2024-2029 (%)
- 12.6.2 Australia - Market size and forecast 2024-2029
- Chart on Australia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Australia - Market size and forecast 2024-2029 ($ billion)
- Chart on Australia - Year-over-year growth 2024-2029 (%)
- Data Table on Australia - Year-over-year growth 2024-2029 (%)
- 12.6.3 UAE - Market size and forecast 2024-2029
- Chart on UAE - Market size and forecast 2024-2029 ($ billion)
- Data Table on UAE - Market size and forecast 2024-2029 ($ billion)
- Chart on UAE - Year-over-year growth 2024-2029 (%)
- Data Table on UAE - Year-over-year growth 2024-2029 (%)
- 12.6.4 South Africa - Market size and forecast 2024-2029
- Chart on South Africa - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Africa - Market size and forecast 2024-2029 ($ billion)
- Chart on South Africa - Year-over-year growth 2024-2029 (%)
- Data Table on South Africa - Year-over-year growth 2024-2029 (%)
- 12.6.5 Saudi Arabia - Market size and forecast 2024-2029
- Chart on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Chart on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- Data Table on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- 12.6.6 Turkey - Market size and forecast 2024-2029
- Chart on Turkey - Market size and forecast 2024-2029 ($ billion)
- Data Table on Turkey - Market size and forecast 2024-2029 ($ billion)
- Chart on Turkey - Year-over-year growth 2024-2029 (%)
- Data Table on Turkey - Year-over-year growth 2024-2029 (%)
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ billion)
- Data Tables on Market opportunity by geography ($ billion)
13 Drivers, Challenges, and Opportunity
- 13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Increasing prevalence of type 2 diabetes and obesity
- Growing awareness and diagnosis of metabolic disorders
- Favorable clinical outcomes and expanding indications
- 13.2 Market challenges
- High cost of therapy and reimbursement challenges
- Side effects and patient tolerability
- Competition from pipeline drugs and alternative therapies
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 13.4 Market opportunities
- Development of multi agonist therapies
- Expansion of indications beyond diabetes
- Shift towards oral and longer acting formulations
14 Competitive Landscape
- 14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15 Competitive Analysis
- 15.1 Companies profiled
- 15.2 Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 Amgen Inc.
- Amgen Inc. - Overview
- Amgen Inc. - Product / Service
- Amgen Inc. - Key news
- Amgen Inc. - Key offerings
- SWOT
- 15.5 Amneal Pharmaceuticals Inc.
- Amneal Pharmaceuticals Inc. - Overview
- Amneal Pharmaceuticals Inc. - Business segments
- Amneal Pharmaceuticals Inc. - Key news
- Amneal Pharmaceuticals Inc. - Key offerings
- Amneal Pharmaceuticals Inc. - Segment focus
- SWOT
- 15.6 Ascendis Pharma AS
- Ascendis Pharma AS - Overview
- Ascendis Pharma AS - Product / Service
- Ascendis Pharma AS - Key offerings
- SWOT
- 15.7 AstraZeneca Plc
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Product / Service
- AstraZeneca Plc - Key news
- AstraZeneca Plc - Key offerings
- SWOT
- 15.8 Boehringer Ingelheim Intl. GmbH
- Boehringer Ingelheim Intl. GmbH - Overview
- Boehringer Ingelheim Intl. GmbH - Product / Service
- Boehringer Ingelheim Intl. GmbH - Key news
- Boehringer Ingelheim Intl. GmbH - Key offerings
- SWOT
- 15.9 Eli Lilly and Co.
- Eli Lilly and Co. - Overview
- Eli Lilly and Co. - Product / Service
- Eli Lilly and Co. - Key offerings
- SWOT
- 15.10 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 15.11 GlaxoSmithKline Plc
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key news
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Segment focus
- SWOT
- 15.12 Innovent Biologics Inc.
- Innovent Biologics Inc. - Overview
- Innovent Biologics Inc. - Product / Service
- Innovent Biologics Inc. - Key offerings
- SWOT
- 15.13 Johnson and Johnson Services Inc.
- Johnson and Johnson Services Inc. - Overview
- Johnson and Johnson Services Inc. - Business segments
- Johnson and Johnson Services Inc. - Key news
- Johnson and Johnson Services Inc. - Key offerings
- Johnson and Johnson Services Inc. - Segment focus
- SWOT
- 15.14 LG Chem Ltd.
- LG Chem Ltd. - Overview
- LG Chem Ltd. - Business segments
- LG Chem Ltd. - Key news
- LG Chem Ltd. - Key offerings
- LG Chem Ltd. - Segment focus
- SWOT
- 15.15 Merck and Co. Inc.
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Business segments
- Merck and Co. Inc. - Key news
- Merck and Co. Inc. - Key offerings
- Merck and Co. Inc. - Segment focus
- SWOT
- 15.16 Novo Nordisk AS
- Novo Nordisk AS - Overview
- Novo Nordisk AS - Business segments
- Novo Nordisk AS - Key offerings
- Novo Nordisk AS - Segment focus
- SWOT
- 15.17 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
- 15.18 Takeda Pharmaceutical Co. Ltd.
- Takeda Pharmaceutical Co. Ltd. - Overview
- Takeda Pharmaceutical Co. Ltd. - Product / Service
- Takeda Pharmaceutical Co. Ltd. - Key news
- Takeda Pharmaceutical Co. Ltd. - Key offerings
- SWOT
16 Appendix
- 16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- 16.5 Data procurement
- 16.6 Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
INFORMATION SOURCES
DATA ANALYSIS
REPORT WRITING
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
